Tri Locum Partners’s Altimmune ALT Stock Holding History

Tri Locum Partners’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-528,814	Closed	-$2.23M	–	63
2023 Q1	$2.23M	Buy	528,814 +203,120	+62%	+$2.41M	0.68%	37
2022 Q4	$5.36M	Buy	325,694 +168,391	+107%	+$1.89M	2.17%	16
2022 Q3	$2.01M	Sell	157,303 -417,343	-73%	-$6.16M	0.55%	35
2022 Q2	$6.72M	Buy	+574,646	New	+$3.54M	2.75%	14

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Tri Locum Partners's ALT Position: Q2 2023 in Review

Tri Locum Partners sold out of Altimmune (ALT) in Q2 2023, closing a stake of 528,814 shares — an estimated $2.23M sold.

Tri Locum Partners first reported a position in ALT in Q2 2022 and held it in 4 quarters. The position peaked at $6.72M in Q2 2022. 120 funds tracked by Wall St. Rank hold ALT as of Q2 2023.

Tri Locum Partners reported no remaining Altimmune position as of Q2 2023 after selling out during the quarter.
Tri Locum Partners sold 528,814 Altimmune shares in Q2 2023, an estimated $2.23M.
Tri Locum Partners first reported a position in Altimmune in Q2 2022 and held it in 4 quarters.
Tri Locum Partners's Altimmune position peaked at $6.72M in Q2 2022.
120 funds tracked by Wall St. Rank held Altimmune as of Q2 2023.

Based on Tri Locum Partners's 13F filing for Q2 2023, filed 14 Aug 2023.